Abstract
P harmacoeconomic evaluation has a tactical role in the early stages of drug development - as early as prephase I and phase I. Reasons for initiating analysis so early include the need to understand the economic viability of a product before large investments are made and to have a clear idea of the product’s pharmacoeconomic advantages. Delegates at Faulkner & Gray’s Drug Outcomes Conference [ Florida, US; December 1994 ] heard Dr Anula Jayasuriya, Director of Outcomes Research at Syntex, elaborate on the early implementation of pharmacoeconomics and outline the concept of an economic ‘me too’ product.
Rights and permissions
About this article
Cite this article
Langsdale, T. Start pharmacoeconomic evaluation early in drug development. Pharmacoecon. Outcomes News 20, 3 (1995). https://doi.org/10.1007/BF03293667
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03293667